Immunocore
Price & Volume
Stats
See more52W Range | $27.69-$72.56 |
Market Cap | $1.4B |
Shares Short | 7M |
Financials
See moreRevenue (12 Mos) | $296.3M |
Revenue Growth (YoY) | 23.7% |
Gross Profit (12 Mos) | $87.5M |
Diluted EPS | -$0.95 |
News
See moreYahoo Finance • 5 months ago
Immunocore Holdings plc (IMCR): Worst 52-Week Low Stock to Buy Now
Yahoo Finance • 5 months ago
Immunocore Holdings plc (IMCR) Hits 52-Week Low Despite 34% Surge in KIMMTRAK Sales
Yahoo Finance • 8 months ago
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
Yahoo Finance • last year
An Intrinsic Calculation For Immunocore Holdings plc (NASDAQ:IMCR) Suggests It's 50% Undervalued
About
CEO | Dr. Bahija Jallal Ph.D. |
CFO | Mr. Travis A. Coy |
Address | 92 Park Drive, Abingdon, United Kingdom, OX14 4RY |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 497 |
